Hypera S.A. (BST:HM6A)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.38B +26.6% |
| Revenue (ttm) | 1.19B +3.4% |
| Net Income | 184.84M -10.9% |
| EPS | 0.29 -10.7% |
| Shares Out | n/a |
| PE Ratio | 12.87 |
| Forward PE | 7.62 |
| Dividend | 0.16 (4.16%) |
| Ex-Dividend Date | Apr 6, 2026 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 3.740 |
| Previous Close | 3.740 |
| Day's Range | 3.680 - 3.840 |
| 52-Week Range | 2.980 - 4.700 |
| Beta | n/a |
| RSI | 47.91 |
| Earnings Date | Apr 28, 2026 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic... [Read more]
Financial Performance
In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.
Financial numbers in BRL Financial StatementsNews
Hypera Earnings Call Transcript: Q1 2026
Q1 2026 saw 87% revenue growth and 9.5% sell-out increase, driven by new launches and logistics gains. Net debt fell 20% after a BRL 1.5B capital increase, with leverage at 2.2x EBITDA. Outlook remains strong with further launches and market share gains expected.
Hypera Earnings Call Transcript: Q4 2025
Sellout grew 6.8% in 2025, with net revenue up 3.4% and record operating cash flow after working capital optimization. Entering 2026, the company expects further efficiency gains, strong cash flow, and growth from new launches, especially semaglutide, pending regulatory approval.
Hypera Earnings Call Transcript: Q3 2025
Net revenue rose 16% year-over-year to BRL 2.2 billion, with EBITDA margin at 34% and record operational cash flow. Retail outperformed the market, while institutional sales declined; strong pipeline and new launches are expected to drive future growth.
Hypera Earnings Call Transcript: Q2 2025
Sell-out grew 5.5% in Q2 2025, outpacing the market, with strong acceleration in May–July. Working capital optimization improved efficiency and margins, while net revenue reached R$2.2 billion and EBITDA margin was 33.7%. Focus remains on deleveraging and sustainable growth.
Brazil's Hypera announces new majority stakeholder group
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.
Hypera Earnings Call Transcript: Q1 2025
Sell-out grew 7% in Q1 2025, but net revenue fell 41% due to working capital optimization, resulting in negative EBITDA and net earnings. Operational cash flow hit a record, and margins are expected to normalize from Q2 as new product launches and efficiency measures take effect.
Hypera Earnings Call Transcript: Q4 2024
Sell-out grew 9% in 2024, but net revenue fell 6% due to working capital optimization, with margins and net income also down. Over 50 new products were launched, and significant investments were made in marketing, R&D, and capacity. Margin recovery and normalized operations are expected in H2 2024.
Hypera Earnings Call Transcript: Q3 2024
Sell-out growth accelerated to 11% in Q3 2024, driven by flu and seasonal products, while working capital optimization reduced revenue and income but boosted free cash flow by 23%. Market share gains, strong innovation, and digital marketing investments support future growth.
Hypera Transcript: Status Update
A new working capital strategy aims to boost cash generation by BRL 2.5 billion by 2028 and BRL 7.5 billion over ten years, with a gradual reduction in receivables and inventories. Short-term financial impacts are expected, but operational efficiency and shareholder value are set to improve from 2026.
Hypera Earnings Call Transcript: Q2 2024
Q2 2024 saw 6.3% sell-out growth, record cash flow, and strong performance in chronic treatments, offsetting weak influenza sales. Guidance for 2024 is reaffirmed, with H2 expected to benefit from market recovery and new product launches.